Issue link: https://viewer.e-digitaledition.com/i/833451
including electrophysiolog y and inter- ventiona l ca rdiolog y," he says. "Our electrophysiolog ists impla nt a tem- porar y pacema ker, placing a screw-in lead through the neck so patients ca n move around and keep the lead in longer, allowing us to watch for complications." In fact, the need for a pacemaker after the procedure is one of the very complica- tions Dr. Naidu is on the lookout for. "We used to place pacemakers intrave- nously through the leg, but patients couldn't keep them in that long," he says. "With the newer approach, they can keep the pace- maker longer with a virtual elimination of associated complications, while becoming mobile soon after their procedure." As a result, the team can tell, while the pacemaker is still in place, whether it will be needed as a long-term assist for the patient. Echocardiography imaging during the procedure is a second innovation Dr. Naidu has embraced. "We have the echocardiography team in the lab the entire case," he says. "We use more echo guidance than fluoroscopic imaging, and we use it to guide the whole procedure, not just during the ablation. Along with the neck-placed pacemaker for added patient safety and comfort, echo guidance throughout the procedure is unique to our program." Dr. Naidu is performing clinical research into minimizing ASA-associated com- plications, such as the risk of needing a perma nent pacema ker. Westchester Medical Center will also be involved with a trial of next-generation pharmaceutical alternatives to standard medical therapy and HCM procedures. A COMPREHENSIVE PROGRAM A n HCM prog ra m must encompa ss patients a nd fa mi ly members a li ke, D r. Pa n z a s ay s . Wr a pa r ou n d c a r e includes disciplines from genetics to psychiatry. Westchester Medical Center o•ers the comprehensive setting to make that possible. "Pediatric ca rdiolog y is impor tant because patients very rarely have HCM at birth but also very rarely develop it as older adults," Dr. Panza says. "The disease often develops during childhood or adolescence, usually during a period of rapid growth. Careful monitoring during these years is essential." Of these patients, first-degree relatives of the index case need to be screened, Dr. Panza says. Therefore, genetics makes an important ancillary to HCM treatment. " S creen i n g shou ld be per for med in the context of a discussion with the parent because the disease has a genetic background that is detectable in only about 50 percent of cases," he says. "There is no single genetic mutation that causes all cases of HCM, so screening is not a simple task." Screening should involve psychiatry as well, Dr. Panza says. "The disease can be debilitating at a physical level for some patients who have symptoms, and yet it can be compatible with a completely normal life for those who do not," he says. "One clear recom- mendation even for HCM patients who have no symptoms is to avoid competitive athletics. For a teenager who is an athlete, that can have a profound psychological impact. Knowing you have a condition that exposes you to the risk of sudden death can be a terrible psychological burden. Hence, our program has the ability to provide appropriate psychological support." This human component, combined with an advanced imaging protocol and Dr. Naidu's experienced clinical and inter- ventional treatments, makes Westchester Medica l Center a key destination for multifaceted HCM care. " We wa nt prima r y ca re physicia ns a nd ca rdiolog ists to know we have a comprehensive program that o•ers a ll potentia l forms of treatment a patient may need," Dr. Pa nza says. " We look forward to collaborating with them." Vi s it westch este r m edical ce nte r.co m /heart to learn more. ■ Dr. Naidu with team members in Westchester Medical Center's Cardiac Catheterization Lab Srihari Naidu, MD, Director of the Hypertrophic Cardiomyopathy Program at Westchester Medical Center 1 0 C O V E R F E A T U R E

